多药耐药相关蛋白和P糖蛋白介导的膀胱肿瘤多药耐药机制的研究进展  

Research Progress of MRP,P-gp Mediated Multidrug Resistance Mechanism of Bladder Tumor

作　　者：代昌远 李庆文[1] 

机构地区：[1]蚌埠医学院第一附属医院泌尿外科,安徽蚌埠233000

出　　处：《医学综述》2013年第22期4097-4099,共3页Medical Recapitulate

摘　　要：膀胱肿瘤是一种最常见的泌尿生殖系统肿瘤,根据来源可分为两种:一种是起源于膀胱本身的原发性肿瘤;另一种是其他器官的肿瘤细胞通过血液、淋巴等侵袭膀胱所导致的继发性肿瘤。膀胱肿瘤的治疗方法主要包括手术治疗、化学治疗、药物治疗等,化疗是治疗肿瘤的最为重要的手段之一,但其疗效往往不尽如人意,主要原因与膀胱肿瘤多药耐药有关。Bladder tumor is one of the most common tumors of the genitourinary system, which can be divided into two types according to the sources：one is primary caneeroriginated from the bladder, the other is secondary tumor originated from cancer ceils of other organs through the blood, lymphatic invasion of the bladder. Bladder cancer treatments include surgery, chemotherapy and drug therapy, while chemotherapy is one of the most important means of tumor treatment,its efficacy is often not satisfactory, with multidrug resist- ance of bladder tumor as the main cause.

关 键 词：多药耐药相关蛋白 P糖蛋白 膀胱肿瘤 肿瘤多药耐药 

分 类 号：R737.14[医药卫生—肿瘤]